Navigation Links
Allied Healthcare Net Falls on Manufacturing Delays
Date:5/12/2008

ST. LOUIS, May 12 /PRNewswire-FirstCall/ -- Allied Healthcare Products, Inc. (Nasdaq: AHPI) reported today that its net income for the third quarter ending March 31 fell 64 percent, from about $278,000 last year, or 4 cents per share, to about $100,000 in the current quarter, or 1 cent per share.

Sales for the third quarter increased by about $240,000 compared to the third quarter of the prior year. However, higher material and labor costs this fiscal year eroded margins and profits for the quarter.

For the first three quarters of the 2008 fiscal year ending March 31, Allied net income fell about 75 percent, from about $772,000 last year, or 10 cents per share, to about $193,000, or 2 cents per share this year.

Customer orders for the first three quarters of fiscal 2008 remained essentially flat compared to the previous period. However, actual sales declined by about $784,000, or about 1.8 percent, primarily because manufacturing delays slowed Allied shipments of some customer orders.

Allied's manufacturing problems led to eroded profit margins and reduced net income. Higher material and labor costs also pressured margins and net income. Allied was able to achieve a modest price increase of 0.8 percent. But that price relief could not offset the combined effects of manufacturing delays and higher costs.

Planned cost reduction efforts began to show positive effects in the last quarter, said Earl Refsland, Allied president and chief executive officer. The company will lower costs by bringing production of some products in house, he said. New investment in equipment is planned to help resolve the manufacturing throughput problem and reduce the cost of machined components.

Allied Healthcare Products,
'/>"/>

SOURCE Allied Healthcare Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Allied Security Holdings LLC to Hold a Conference Call to Discuss Fiscal Year 2007 Results on Thursday, March 27, 2008 at 11:00 AM EDT
2. C.V. Starr & Company to Offer Management Liability Lines From Allied World Assurance Company
3. Allied Healthcares Net Suffers on Flat Sales, Performance Issues
4. Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting
5. SIEMENS, AlliedBarton, Methodist Hospital, and Family Planning Council Win Human Resources Department of the Year Awards
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. 34 SEIU Healthcare Leaders Urge UHW-W Members to Join in Support of New Plan to Win Quality Healthcare for All, Build Strength of Healthcare Workers
8. Retiring Nurses See Healthcare Advocacy as Second Career - Healthcare Liaison Workshop June 7-8 Shows Them How to Make Transition
9. New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health
10. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
11. Watson to Present at the Bank of America 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Beverage Can Stay Tabs Pose Swallowing Risk 62223 1Beverage Can Stay Tabs Pose Swallowing Risk 62223 2New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 1New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 2New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 3Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 1Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 2Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 3